Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
Zi-Xuan Wang1, Qing-Qing Li1, Jiao Cai1
1National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Abstract:
Over the past decades, the role of rearranged during transfection (RET) alterations in tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic target in patients with RET-altered cancers. In clinical practice, initial efficacy can be achieved in patients through the utilization of multikinase inhibitors (MKIs) with RET inhibitory activity. However, the effectiveness of these MKIs is impeded by the adverse events associated with off-target effects. Recently, many RET-selective inhibitors, characterized by heightened specificity and potency, have been developed, representing a substantial breakthrough in the field of RET precision oncology. This Perspective focuses on the contemporary understanding of RET mutations, recent advancements in next-generation RET inhibitors, and the challenges associated with resistance to RET inhibitors. It provides valuable insights for the development of next-generation MKIs and selective RET inhibitors.
Insights
Rearranged during transfection (RET) alterations drive cancer, and while multikinase inhibitors show initial efficacy, their off-target effects limit treatment. Next-generation RET-selective inhibitors offer improved precision oncology for RET-altered cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Rearranged during transfection (RET) alterations are key drivers in various cancers.
- RET kinase inhibition is a critical therapeutic strategy for RET-altered malignancies.
- Current multikinase inhibitors (MKIs) targeting RET have limitations due to off-target effects and adverse events.
Purpose of the Study:
- To review the current understanding of RET mutations in tumorigenesis.
- To discuss advancements in next-generation RET inhibitors.
- To explore challenges related to resistance mechanisms against RET inhibitors.
Main Methods:
- Literature review of RET alterations and inhibitor development.
- Analysis of clinical data on multikinase inhibitors and selective RET inhibitors.
- Discussion of emerging resistance patterns and future therapeutic directions.
Main Results:
- Next-generation RET inhibitors demonstrate enhanced specificity and potency.
- Selective RET inhibitors represent a significant breakthrough in precision oncology.
- Understanding resistance mechanisms is crucial for optimizing future therapies.
Conclusions:
- RET-selective inhibitors offer a promising therapeutic avenue for RET-altered cancers.
- Further research into overcoming resistance is essential for durable clinical responses.
- This perspective provides insights for developing improved RET-targeted therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...